Nsgene Inc. | Date: 2012-09-05
The present invention relates to use of Cometin in a method of treatment of allodynia, hyperalgesia, spontaneous pain and/or phantom pain. In a preferred embodiment the disorder to be treated is thermal allodynia and thermal hyperalgesia. The Cometin polypeptide may be delivered as a polypeptide or by administration of an expression vector for expression of Cometin, a cell line transformed or transduced with said vector and a capsule comprising said cells.
Nsgene Inc. | Date: 2012-12-14
The present invention relates to the field of therapeutic use of proteins, genes and cells, in particular to the therapy based on the biological function of a secreted therapeutic protein, METRNL, in particular for the treatment of disorders of the nervous system. METRNL is a Nerve Survival and Growth factor with neuroprotective and/or neurogenesis effects.
Nsgene Inc. | Date: 2015-08-07
The present invention relates to generation of cell lines expressing recombinant proteins for use in naked and encapsulated cell biodelivery of secreted therapeutic molecules. In one embodiment the cell line is human. In another aspect of the invention the transposon system is used for generating a cell line for secretion of a biologically active polypeptide.
Agency: Cordis | Branch: FP7 | Program: MC-ITN | Phase: FP7-PEOPLE-2010-ITN | Award Amount: 3.76M | Year: 2011
Protein aggregation is a hallmark of many late onset neurodegenerative disorders including Parkinsons Disease (PD), Alzheimers Disease (AD), amyotrophic lateral sclerosis (ALS), prion diseases as well as the group of polyglutamine diseases (polyQ). The aim of this proposal is to create a network of European partners bridging important basic mechanisms involved in proteinopathies, research of model diseases and treatment approaches. The TreatPolyQ network will focus on two main representatives of the polyQ diseases: Huntingtons disease as the most common polyQ disease as well as spinocerebellar ataxia type 3 (SCA3) as the most frequent autosomal-dominantly inherited ataxia. Patients suffer from a multitude of neurological symptoms including movement abnormalities with late onset and in a progressive manner. Up to now, no treatment or cure is available. The network will be consisting of a rare combination of experts from basic and translational research, including a Nobel prize laureate, four industrial partners (two medium, and two small companies, all incorporated as full participants) and academic leaders of the field. The network not only focuses on one special aspect of a disease but spans several important disease-associated mechanism as well as promising treatment strategies for HD and SCA3 (protein transport, protein folding, protein degradation via both the ubiquitin-proteasome system and autophagy), likely to be important across a range of neurodegenerative diseases. In order to implement these research projects, extensive collaborations and temporarily personnel secondments of the involved researchers will take place, enhancing interdisciplinary transfer of knowledge. Beyond the personalized local training plan for each employed researcher within the Network, there will be 4 structured courses covering aspects ranging from structural biology to protein degradation to model organisms and drug development, including soft skill training.
Nsgene Inc. | Date: 2014-08-22
The present invention relates to the use of Meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain. In a preferred embodiment the disorder to be treated is allodynia, and hyperalgesia, more preferably allodynia including thermal and tactile allodynia.